July 28, 2016

Novocure to Host Research and Development Day on Dec. 12, 2016

July 28, 2016 06:25 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST… Read More
learn more
July 28, 2016

Novocure to Host Research and Development Day on Dec. 12, 2016

July 28, 2016 06:25 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST… Read More
learn more
July 26, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate July 26, 2016 09:46 AM Eastern Daylight Time ST. HELIER,… Read More
learn more
July 26, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate July 26, 2016 09:46 AM Eastern Daylight Time ST. HELIER,… Read More
learn more
July 26, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate July 26, 2016 09:46 AM Eastern Daylight Time ST. HELIER,… Read More
learn more
July 13, 2016

Novocure Receives FDA Approval for Second Generation Optune System

Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients Novocure’s new system aims to make Optune therapy even easier for… Read More
learn more
July 13, 2016

Novocure Receives FDA Approval for Second Generation Optune System

Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients Novocure’s new system aims to make Optune therapy even easier for… Read More
learn more
July 13, 2016

Novocure Receives FDA Approval for Second Generation Optune System

Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients Novocure’s new system aims to make Optune therapy even easier for… Read More
learn more
June 30, 2016

Novocure to Report Second Quarter 2016 Financial Results

June 30, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2016 on Thursday, July 28, 2016 at 6:30 a.m. EDT before the open of… Read More
learn more
June 30, 2016

Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors

Non-dilutive financing enhances financial strength Non-dilutive financing enhances financial strength June 30, 2016 04:00 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it has provided notice to draw the remaining $75… Read More
learn more